10 Best Healthcare Moat Stocks for February 2026
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The healthcare sector continues to demonstrate resilience amid broader market volatility, driven by aging populations, innovation in pharmaceuticals, and steady demand for medical devices and biotech solutions. Value Sense's analysis highlights companies with strong economic moats—sustainable competitive advantages like high gross margins, robust ROIC, and consistent free cash flow generation. These top 10 healthcare moat stocks were selected using Value Sense's proprietary methodology, focusing on Quality rating above 6.0, elevated intrinsic value estimates suggesting undervaluation potential, high gross margins (typically 60%+), and superior ROIC metrics indicating efficient capital allocation. Stocks were curated from pre-built watchlists emphasizing healthcare themes, prioritizing those with strong FCF margins and revenue visibility for long-term holding. This watchlist targets undervalued stocks to buy in biotech, pharma, and medtech subsectors, providing a diversified stock picks overview for retail investors.
Featured Stock Analysis
Stock #1: Eli Lilly and Company (LLY)
| Metric | Value |
|---|---|
| Market Cap | $928.7B |
| Quality Rating | 7.9 |
| Intrinsic Value | $276.8 |
| 1Y Return | 26.2% |
| Revenue | $59.4B |
| Free Cash Flow | $9,020.7M |
| Revenue Growth | 45.4% |
| FCF margin | 15.2% |
| Gross margin | 83.0% |
| ROIC | 36.0% |
| Total Debt to Equity | 178.2% |
Investment Thesis
Eli Lilly and Company (LLY) stands out as a healthcare leader with a Quality rating of 7.9, the highest in this watchlist, backed by explosive revenue growth of 45.4% and a massive $59.4B in revenue. Its intrinsic value of $276.8 points to potential undervaluation, supported by impressive ROIC at 36.0% and gross margin of 83.0%. Generating $9,020.7M in free cash flow with a 15.2% FCF margin, LLY demonstrates powerful cash generation amid a $928.7B market cap. The 26.2% 1Y Return reflects market recognition of its moat in innovative therapies, positioning it for sustained growth in a sector favoring high-quality compounders.
This analysis underscores LLY's efficiency, with high margins and returns signaling a durable competitive edge in pharmaceuticals.
Key Catalysts
- Exceptional 45.4% revenue growth driving scale in blockbuster drugs
- 36.0% ROIC highlighting superior capital efficiency
- 83.0% gross margin supporting R&D reinvestment
Risk Factors
- Elevated 178.2% total debt to equity requiring debt management focus
- Dependence on key drug pipelines amid patent cliffs
Stock #2: AstraZeneca PLC (AZN)
| Metric | Value |
|---|---|
| Market Cap | $291.4B |
| Quality Rating | 7.0 |
| Intrinsic Value | $76.7 |
| 1Y Return | 32.0% |
| Revenue | $58.1B |
| Free Cash Flow | $11.1B |
| Revenue Growth | 13.5% |
| FCF margin | 19.2% |
| Gross margin | 82.3% |
| ROIC | 15.6% |
| Total Debt to Equity | 71.0% |
Investment Thesis
AstraZeneca PLC (AZN) earns a solid Quality rating of 7.0, with $58.1B revenue and 13.5% revenue growth fueling a 32.0% 1Y Return. Its intrinsic value of $76.7 suggests room for appreciation in a $291.4B market cap profile. Strong free cash flow of $11.1B at a 19.2% FCF margin, combined with 82.3% gross margin and 15.6% ROIC, illustrates a reliable moat in oncology and rare diseases. This positions AZN as a steady performer in global pharma markets.
Balanced metrics make AZN a cornerstone for healthcare exposure.
Key Catalysts
- 32.0% 1Y return from pipeline momentum
- $11.1B free cash flow enabling dividends and buybacks
- 82.3% gross margin for profitability resilience
Risk Factors
- 71.0% total debt to equity in a high-interest environment
- Regulatory hurdles in international expansions
Stock #3: Merck & Co., Inc. (MRK)
| Metric | Value |
|---|---|
| Market Cap | $273.2B |
| Quality Rating | 7.2 |
| Intrinsic Value | $116.1 |
| 1Y Return | 11.4% |
| Revenue | $64.2B |
| Free Cash Flow | $13.0B |
| Revenue Growth | 1.7% |
| FCF margin | 20.3% |
| Gross margin | 82.8% |
| ROIC | 30.1% |
| Total Debt to Equity | 79.8% |
Investment Thesis
Merck & Co., Inc. (MRK) features a Quality rating of 7.2, largest revenue at $64.2B, and top-tier $13.0B free cash flow with 20.3% FCF margin. Despite modest 1.7% revenue growth, its 30.1% ROIC, 82.8% gross margin, and intrinsic value of $116.1 highlight undervaluation potential in a $273.2B market cap. The 11.4% 1Y Return aligns with its defensive moat in vaccines and oncology.
MRK's cash flow strength supports long-term stability.
Key Catalysts
- Leading $13.0B free cash flow for innovation funding
- 30.1% ROIC demonstrating operational excellence
- 82.8% gross margin buffering sector pressures
Risk Factors
- Slow 1.7% revenue growth signaling pipeline risks
- 79.8% total debt to equity amid economic shifts
Stock #4: Novo Nordisk A/S (NVO)
| Metric | Value |
|---|---|
| Market Cap | $263.1B |
| Quality Rating | 6.2 |
| Intrinsic Value | $87.4 |
| 1Y Return | -30.4% |
| Revenue | DKK 315.6B |
| Free Cash Flow | DKK 62.7B |
| Revenue Growth | 16.6% |
| FCF margin | 19.9% |
| Gross margin | 82.0% |
| ROIC | 27.2% |
| Total Debt to Equity | 59.6% |
Investment Thesis
Novo Nordisk A/S (NVO) holds a Quality rating of 6.2, with DKK 315.6B revenue, 16.6% revenue growth, and DKK 62.7B free cash flow at 19.9% FCF margin. Intrinsic value at $87.4 and 82.0% gross margin suggest value in its $263.1B market cap, despite -30.4% 1Y Return. 27.2% ROIC reinforces its diabetes and obesity treatment moat.
NVO offers growth recovery potential.
Key Catalysts
- 16.6% revenue growth in high-demand therapies
- 27.2% ROIC for efficient expansion
- Strong 19.9% FCF margin in DKK terms
Risk Factors
- -30.4% 1Y return indicating volatility
- 59.6% total debt to equity exposure
Stock #5: Gilead Sciences, Inc. (GILD)
| Metric | Value |
|---|---|
| Market Cap | $175.1B |
| Quality Rating | 7.0 |
| Intrinsic Value | $103.1 |
| 1Y Return | 46.4% |
| Revenue | $29.1B |
| Free Cash Flow | $9,667.0M |
| Revenue Growth | 2.8% |
| FCF margin | 33.2% |
| Gross margin | 78.7% |
| ROIC | 21.9% |
| Total Debt to Equity | 0.0% |
Investment Thesis
Gilead Sciences, Inc. (GILD) scores 7.0 Quality rating, with standout 46.4% 1Y Return and $9,667.0M free cash flow at exceptional 33.2% FCF margin. $29.1B revenue, 78.7% gross margin, 21.9% ROIC, and intrinsic value of $103.1 position it well in a $175.1B market cap. Zero total debt to equity enhances its balance sheet moat in antivirals and oncology.
GILD exemplifies cash-rich stability.
Key Catalysts
- 46.4% 1Y return from HIV and cancer portfolios
- 33.2% FCF margin leading the watchlist
- Debt-free balance sheet 0.0%
Risk Factors
- Modest 2.8% revenue growth
- Patent expirations on key products
Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.
Want to see what we'll uncover next - before everyone else does?
Find Hidden Gems First!
Stock #6: Medtronic plc (MDT)
| Metric | Value |
|---|---|
| Market Cap | $130.7B |
| Quality Rating | 6.6 |
| Intrinsic Value | $110.2 |
| 1Y Return | 11.9% |
| Revenue | $34.8B |
| Free Cash Flow | $5,206.0M |
| Revenue Growth | 5.3% |
| FCF margin | 15.0% |
| Gross margin | 62.3% |
| ROIC | 18.9% |
| Total Debt to Equity | N/A |
Investment Thesis
Medtronic plc (MDT) has a 6.6 Quality rating, $34.8B revenue, and $5,206.0M free cash flow at 15.0% FCF margin. Intrinsic value of $110.2, 62.3% gross margin, and 18.9% ROIC support its $130.7B market cap, with 11.9% 1Y Return and 5.3% revenue growth in medtech devices.
MDT provides defensive healthcare diversification.
Key Catalysts
- Steady 5.3% revenue growth in devices
- 18.9% ROIC for medtech leadership
- Reliable free cash flow generation
Risk Factors
- Lower 62.3% gross margin vs. pharma peers
- N/A total debt to equity data warrants caution
Stock #7: Vertex Pharmaceuticals Incorporated (VRTX)
| Metric | Value |
|---|---|
| Market Cap | $120.6B |
| Quality Rating | 6.9 |
| Intrinsic Value | $237.1 |
| 1Y Return | 7.2% |
| Revenue | $11.7B |
| Free Cash Flow | $3,337.2M |
| Revenue Growth | 10.5% |
| FCF margin | 28.5% |
| Gross margin | 86.3% |
| ROIC | 57.5% |
| Total Debt to Equity | 21.2% |
Investment Thesis
Vertex Pharmaceuticals Incorporated (VRTX) boasts a 6.9 Quality rating, top ROIC at 57.5%, and 86.3% gross margin. $11.7B revenue, 10.5% revenue growth, $3,337.2M free cash flow (28.5% margin), and intrinsic value of $237.1 highlight upside in its $120.6B market cap. 7.2% 1Y Return reflects cystic fibrosis dominance.
VRTX's efficiency metrics shine.
Key Catalysts
- Industry-leading 57.5% ROIC
- 86.3% gross margin in biotech
- 10.5% revenue growth trajectory
Risk Factors
- Pipeline concentration risks
- 21.2% total debt to equity
Stock #8: Regeneron Pharmaceuticals, Inc. (REGN)
| Metric | Value |
|---|---|
| Market Cap | $77.8B |
| Quality Rating | 6.7 |
| Intrinsic Value | $867.8 |
| 1Y Return | 8.7% |
| Revenue | $14.3B |
| Free Cash Flow | $3,158.5M |
| Revenue Growth | 1.0% |
| FCF margin | 22.0% |
| Gross margin | 85.6% |
| ROIC | 19.3% |
| Total Debt to Equity | 5.3% |
Investment Thesis
Regeneron Pharmaceuticals, Inc. (REGN) rates 6.7 in Quality, with standout intrinsic value of $867.8 and $14.3B revenue. 22.0% FCF margin on $3,158.5M free cash flow, 85.6% gross margin, and 19.3% ROIC bolster its $77.8B market cap. 8.7% 1Y Return and low 1.0% revenue growth indicate steady eye and oncology moat.
REGN offers high-upside valuation.
Key Catalysts
- $867.8 intrinsic value suggesting deep discount
- 85.6% gross margin strength
- Low 5.3% total debt to equity
Risk Factors
- Minimal 1.0% revenue growth
- Biotech R&D uncertainties
Stock #9: Zoetis Inc. (ZTS)
| Metric | Value |
|---|---|
| Market Cap | $54.4B |
| Quality Rating | 6.7 |
| Intrinsic Value | $101.3 |
| 1Y Return | -27.7% |
| Revenue | $9,397.0M |
| Free Cash Flow | $2,240.0M |
| Revenue Growth | 2.7% |
| FCF margin | 23.8% |
| Gross margin | 71.0% |
| ROIC | 18.6% |
| Total Debt to Equity | 134.7% |
Investment Thesis
Zoetis Inc. (ZTS) scores 6.7 Quality rating, with $9,397.0M revenue, 23.8% FCF margin on $2,240.0M free cash flow, and 71.0% gross margin. Intrinsic value of $101.3 and 18.6% ROIC in a $54.4B market cap, despite -27.7% 1Y Return and 2.7% revenue growth, signal animal health recovery potential.
ZTS diversifies into veterinary moats.
Key Catalysts
- 23.8% FCF margin for pet/human health parallels
- 71.0% gross margin durability
- Established animal pharma positioning
Risk Factors
- -27.7% 1Y return volatility
- 134.7% total debt to equity
Stock #10: IDEXX Laboratories, Inc. (IDXX)
| Metric | Value |
|---|---|
| Market Cap | $54.0B |
| Quality Rating | 7.3 |
| Intrinsic Value | $240.6 |
| 1Y Return | 58.1% |
| Revenue | $4,167.4M |
| Free Cash Flow | $953.6M |
| Revenue Growth | 8.4% |
| FCF margin | 22.9% |
| Gross margin | 61.7% |
| ROIC | 47.8% |
| Total Debt to Equity | 25.3% |
Investment Thesis
IDEXX Laboratories, Inc. (IDXX) leads with 7.3 Quality rating and 58.1% 1Y Return. $4,167.4M revenue, 8.4% revenue growth, $953.6M free cash flow (22.9% margin), 47.8% ROIC, and intrinsic value of $240.6 in a $54.0B market cap. 61.7% gross margin cements its diagnostics moat.
IDXX shows top momentum.
Key Catalysts
- 58.1% 1Y return leadership
- 47.8% ROIC excellence
- 8.4% revenue growth in vet diagnostics
Risk Factors
- Smaller scale vs. mega-caps
- 25.3% total debt to equity
Portfolio Diversification Insights
These top 10 healthcare moat stocks create a balanced portfolio spanning big pharma (LLY, AZN, MRK, NVO), biotech (GILD, VRTX, REGN), medtech (MDT), and animal health (ZTS, IDXX). Sector allocation favors pharmaceuticals 60% for stability, with biotech 25% adding growth and medtech/animal health 15% providing defensiveness. High average ROIC 28.5% and gross margins 77.8% across the group enhance moat durability. LLY and IDXX offer high-quality growth anchors, while GILD's zero debt complements leveraged peers like LLY. Cross-references include shared oncology exposure (AZN, MRK, REGN) and cash flow leaders (MRK, GILD) reducing correlation risks. This mix targets portfolio diversification in healthcare stock picks, mitigating single-drug reliance.
Market Timing & Entry Strategies
Consider positions during sector pullbacks, such as post-earnings dips or when intrinsic value discounts exceed 20% (e.g., REGN, VRTX). Ladder entries over 3-6 months to average into volatile names like NVO or ZTS. Monitor ROIC stability and FCF growth for confirmation, favoring dips below 1-year averages for LLY or IDXX. Use Value Sense screeners for real-time undervalued stocks signals, entering on macroeconomic tailwinds like rate cuts boosting healthcare valuations. Scale based on quality ratings, overweighting 7.0+ like LLY, GILD, IDXX.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- Nelson Peltz - Trian Fund Management Portfolio Q3'2025: Top Holdings & Recent Changes
- Principles for Dealing with the Changing World Order by Ray Dalio
- The Ascent of Money by Niall Ferguson
- Principles for Navigating Big Debt Crises by Ray Dalio
- Influence: The Psychology of Persuasion by Robert B. Cialdini Ph.D.
FAQ Section
How were these stocks selected?
These healthcare moat stocks were chosen using Value Sense's criteria: Quality rating >6.0, high ROIC and gross margins, strong FCF, and intrinsic value indicating undervaluation, from curated healthcare watchlists.
What's the best stock from this list?
LLY leads with the highest 7.9 Quality rating, 45.4% revenue growth, and 36.0% ROIC, making it a standout for quality-focused analysis among these top stocks to buy now.
Should I buy all these stocks or diversify?
Diversify across the 10 for balanced healthcare stock picks—allocate 40-50% to pharma giants (LLY, MRK), 30% biotech, 20% medtech/animal health—to leverage complementary moats while managing risks.
What are the biggest risks with these picks?
Key concerns include high debt levels (e.g., LLY's 178.2%, ZTS 134.7%), pipeline dependencies, regulatory changes, and revenue growth variability (e.g., MRK's 1.7%), common in healthcare analysis.
When is the best time to invest in these stocks?
Optimal entry during market dips when prices approach intrinsic values (e.g., VRTX at $237.1, IDXX at $240.6), or on positive FCF/earnings beats, using Value Sense tools for timing investment opportunities.